CPP-115

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction, infantile spasms, and Tourette syndrome. CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction, infantile spasms, and Tourette syndrome. CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.

History

CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances. It was licensed to Catalyst Pharmaceuticals for development in 2009. CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission. As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.

See also

List of investigational Tourette's syndrome drugs

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083060 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.